'Best of both worlds' -- Targeting a single gene could inhibit bone decay and stimulate bone growth
May lead to drug treatments for osteoporosis
(PHILADELPHIA) -- Researchers at the University of Pennsylvania’s School of Medicine have found by targeting the function of a single gene that it is possible to inhibit bone decay while simultaneously stimulating bone formation. This concept may lead to drug treatments for osteoporosis and other bone diseases. Senior author Yongwon Choi, PhD, professor of Pathology and Laboratory Medicine at the University of Pennsylvania and colleagues report their findings in the December issue of Nature Medicine.
Osteoporosis is a major quality of life issue for the millions of senior citizens in the United States and will only become a bigger problem as the population continues to age.
"The main challenge is how to prevent bone decay while also encouraging bone growth," said Choi.
The basic principles behind bone metabolism are largely understood, hence a handful of drugs treating osteoporosis are available. Most drugs inhibit osteoclasts, which cause bone decay. But there is also at least one that stimulates osteoblasts, enhancing bone formation. A combined treatment will not only prevent the occurrence of osteoporosis, but also make the quality of bone even better.
"Our discovery proves that inhibiting osteoclasts while simultaneously stimulating new bone formation can be done."
Bone health is maintained by the balanced activities of osteoblasts and osteoclasts. The study shows that the inactivation of gene Atp6v0d2 in mice results in dramatically increased bone mass due to defective osteoclasts as well as enhanced bone formation. These findings may provide some clarity into the regulation of bone metabolism and show that targeting the function of a single gene could possibly inhibit bone decay while stimulating bone formation.
"We have finally proven the theory that targeting one gene can do both," said Choi. "Now that we have demonstrated a new approach that is theoretically attainable, one that combines the best of both worlds, we can go to work on the genes up and down stream from our target gene. If we can find a way to get to our target gene with a drug we may be able to help the millions of seniors with osteoporosis."
Dr. Choi was recently named the 2006 winner of Korea’s prestigious Ho-Am Prize for his work in osteoimmunology. The award recognizes scholars and researchers who make outstanding achievements by international standards while encouraging future activities of even higher levels and who also present exemplary models for the academic community. Choi, who is originally from Seoul, South Korea, has been at the University of Pennsylvania since 2001.
PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
Published on PsychCentral.com. All rights reserved.